Equities analysts expect Ionis Pharmaceuticals Inc (NASDAQ:IONS) to announce ($0.11) earnings per share for the current fiscal quarter, according to Zacks Investment Research. Two analysts have made estimates for Ionis Pharmaceuticals’ earnings. The highest EPS estimate is $0.10 and the lowest is ($0.39). The company is scheduled to report its next earnings results on Tuesday, November 6th.

According to Zacks, analysts expect that Ionis Pharmaceuticals will report full year earnings of ($0.36) per share for the current year, with EPS estimates ranging from ($1.10) to $0.03. For the next year, analysts forecast that the business will post earnings of $0.25 per share, with EPS estimates ranging from ($1.60) to $2.49. Zacks’ EPS averages are an average based on a survey of analysts that follow Ionis Pharmaceuticals.

Ionis Pharmaceuticals (NASDAQ:IONS) last announced its earnings results on Tuesday, August 7th. The company reported ($0.29) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.09) by ($0.20). The company had revenue of $117.75 million for the quarter, compared to analyst estimates of $128.22 million. Ionis Pharmaceuticals had a negative return on equity of 1.22% and a negative net margin of 7.20%.

A number of research analysts have recently issued reports on IONS shares. Morgan Stanley dropped their price objective on Ionis Pharmaceuticals to $52.00 and set an “equal weight” rating on the stock in a research note on Monday, May 7th. Stifel Nicolaus decreased their target price on Ionis Pharmaceuticals from $55.00 to $48.00 and set a “hold” rating for the company in a research report on Tuesday, August 7th. Zacks Investment Research lowered Ionis Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Tuesday, July 17th. ValuEngine raised Ionis Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Thursday, August 9th. Finally, BMO Capital Markets upped their target price on Ionis Pharmaceuticals from $70.00 to $75.00 and gave the company an “outperform” rating in a report on Monday, April 23rd. Three investment analysts have rated the stock with a sell rating, six have assigned a hold rating and two have assigned a buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average price target of $52.78.

In related news, Director Frederick T. Muto sold 15,000 shares of the firm’s stock in a transaction that occurred on Thursday, May 31st. The shares were sold at an average price of $46.45, for a total transaction of $696,750.00. Following the completion of the sale, the director now owns 22,127 shares of the company’s stock, valued at $1,027,799.15. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP C Frank Bennett sold 12,500 shares of the firm’s stock in a transaction that occurred on Wednesday, August 8th. The shares were sold at an average price of $45.00, for a total transaction of $562,500.00. Following the sale, the senior vice president now directly owns 19,409 shares of the company’s stock, valued at approximately $873,405. The disclosure for this sale can be found here. Insiders have sold 42,656 shares of company stock valued at $1,901,087 over the last quarter. Company insiders own 2.44% of the company’s stock.

Hedge funds have recently modified their holdings of the company. Baillie Gifford & Co. lifted its stake in shares of Ionis Pharmaceuticals by 48.2% during the 2nd quarter. Baillie Gifford & Co. now owns 9,279,730 shares of the company’s stock valued at $386,687,000 after buying an additional 3,017,079 shares in the last quarter. Summit Trail Advisors LLC lifted its stake in Ionis Pharmaceuticals by 2,960.4% in the 1st quarter. Summit Trail Advisors LLC now owns 523,108 shares of the company’s stock worth $523,000 after purchasing an additional 506,015 shares in the last quarter. First Light Asset Management LLC lifted its stake in Ionis Pharmaceuticals by 1,064.2% in the 2nd quarter. First Light Asset Management LLC now owns 494,347 shares of the company’s stock worth $20,599,000 after purchasing an additional 451,883 shares in the last quarter. BB Biotech AG increased its holdings in shares of Ionis Pharmaceuticals by 4.7% in the 1st quarter. BB Biotech AG now owns 8,516,334 shares of the company’s stock worth $375,400,000 after buying an additional 380,000 shares during the last quarter. Finally, Peregrine Capital Management LLC bought a new stake in shares of Ionis Pharmaceuticals in the 2nd quarter worth about $13,616,000. 94.19% of the stock is owned by hedge funds and other institutional investors.

Shares of NASDAQ:IONS opened at $51.42 on Tuesday. The stock has a market capitalization of $6.69 billion, a PE ratio of 642.75 and a beta of 2.66. The company has a debt-to-equity ratio of 0.76, a quick ratio of 8.34 and a current ratio of 8.38. Ionis Pharmaceuticals has a 1 year low of $39.07 and a 1 year high of $65.51.

About Ionis Pharmaceuticals

Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; and Kynamro an oligonucleotide inhibitor for use in patients with homozygous familial hypercholesterolemia to reduce low density lipoprotein-cholesterol, apolipoprotein B, total cholesterol, and non-high density lipoprotein.

Featured Story: Asset Allocation

Get a free copy of the Zacks research report on Ionis Pharmaceuticals (IONS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Ionis Pharmaceuticals (NASDAQ:IONS)

Receive News & Ratings for Ionis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.